Events

Archives

ExLPharma's Pharmaceutical Pricing & Reimbursement Conference: Managing the Growing Impact of Diagnostics on Access to Pharmaceuticals
July 15th, 2008, New Brunswick, NJ
Presented by: David Parker, Vice President of Boston Healthcare - Participants attended this discussion at ExL Pharma's 4th annual conference to learn how to manage drugs from development through to the marketplace. This presentation also addressed key strategic issues, such as, the pros and cons of pursuing a broad market vs. the highest effectiveness, understanding how clinical trials can affect coverage policy, and how to determine optimum pricing for a diagnostically selected population. Please click here to learn more about the conference or to obtain conference materials.

SMi's Pharmaceutical Portfolio & Product Life-Cycle Management Conference
July 1st - 3rd, 2008, London, England
Sponsored by: Boston Healthcare - Participants attended SMi's 3rd annual conference to learn about strategic portfolio management and planning, licensing and life-cycle management, forecasting analyses and risk assessment, deal strategies, and pricing and reimbursement in the US and EU. Please click here for more information or to obtain conference materials.

F-D-C Reports, Windhover Information and Boston Healthcare Associates proudly present: Adapting to the Changing Dossier Environment - Creating Pharmacoeconomic and Health Outcomes Data That Will Impact Coverage and Formulary Decisions
Thursday, June 26th, 2008, 12 PM EST / 9 AM PT, 90 minutes
Presented by: Phil Cyr - US health care payers have increased their efforts to incorporate pharmacoeconomic and health outcomes data into their coverage and formulary decisions. In addition to budget-impact, quality-of-life, and cost-of-illness information for your new products, the AMCP dossier is now emphasizing the need for greater transparency of health economic and outcomes data submitted, especially cost-effectiveness models. For more information, please visit www.windhover.com/ezine/html/AC0608-2web.htm.

Pharmaceutical Executive Interactive Webcast: Value-Based Reimbursement - New Strategies for a Changing Marketplace
June 4th, 2008, 2:00 PM EST / 11:00 AM PST
Presented by: David Parker, Ph.D. and Gina Ford of Boston Healthcare and Terry Cato of Actelion Pharmaceuticals - Participants attended this webcast and learned how to gain a strategic advantage for drugs in today’s market: they learned how value-based reimbursement meets the needs of stakeholders in today’s pharmaceutical marketplace; learned about new reimbursement approaches - and when traditional tactics aren't enough; and discussed the benefits of this new approach for drug’s prospects in the market. For more information visit www.pharmexec.com/reimbursement

The Larta Institute's 2008 Life Sciences Venture Forum
May 30th, 2008, Santa Clara Convention Center
Sponsor: Boston Healthcare – The Venture Forum is the showcase component of the Larta Institute's Commercialization Assistance Practice; a set of year-round programs that uncover, coach and train innovators funded by institutions such as the National Institutes of Health, the US Department of Agriculture, and a network of over 30 leading universities and research institutions from around of the globe. Participants met with Boston Healthcare at the 2008 Venture Forum to learn about strategies that are critical to commercialization success. Click here for more information.

MassMedic - Issue Briefing: Inpatient Prospective Payment System (IPPS) Proposed Rule
Thursday, May 15th, 2008, 8:00 a.m. – 9:30 a.m., PRTM, 1050 Winter Street, Waltham, Massachusetts
Presenters: Charles Mathews, Director and Erica Bisguier, Executive Director - The Centers for Medicare & Medicare Services (CMS) released the FY 2009 proposed rule which describes potential upcoming changes to the ways hospitals are paid for inpatient care under Medicare's inpatient prospective payment system (IPPS). This briefing reviewed the substantial IPPS reforms begun last year, examined the modifications for FY 2009, and described the impact of these changes on sales and marketing strategies for medical device companies.

ISPOR Annual International Conference
May 5 - 7th, 2008, Toronto, Canada
Exhibitor: Boston Healthcare – Participants attended the 13th Annual International Society for Pharmacoeconomics and Outcomes Research Conference to learn from top outcomes researchers and health care decision-makers from a variety of work environments including the pharmaceutical and biotechnology industries, clinical practice, government agencies, academia and managed care. Click here for more information.

Molecular Diagnostics Tri-Conference: Assessing and Capturing Value in Companion Diagnostics
March 27th 2008, San Francisco, CA
Expert Panel Speaker: Joseph Ferrara, Executive Vice President – Attendees at this session learned valuable answers to such questions as: What component drives the process, the drug or the diagnostic? Where does the ownership lie? When a diagnostic is linked to a targeted therapeutic, how is each component valued by the diagnostic? By the pharma? Click here for more information.

Medtech Insight's In3 West Investment in Innovation Conference
February 27th - 29th, 2008, Las Vegas, Nevada
Sponsored by Boston Healthcare, In3 West is an ideal opportunity to invest, partner and network with the most promising early- to late-stage medical technology companies and the biggest deal makers in the medtech business development and investment communities. Click here for more information.

MDG Meeting – January Networking Event: Evidence Based Medicine for Clinical Trial Design
January 23rd 2008, 5:30 p.m., Newton, Massachusetts
Speaker: Erica Bisguier, Executive Director – As medical technologies become more complex, and information technology systems more sophisticated, public and private payers are increasingly relying on comprehensive clinical and economic evidence to drive coverage and payment. Many payers have developed rigorous technology assessment processes that can either facilitate or impede clinician and market access. This session provided suggestions for the practical application of EBM in clinical development, commercialization activities and timelines. Click here for more information.

IBC Life Sciences' Nucleic Acid Technologies for Diagnostics Conference: Challenges in Assessing and Capturing Value in the Commercial Environment
December 5th 2007, Berlin, Germany
Speaker: Rob Wenthold, Director - Participants attended Europe's only event to address the key regulatory, manufacturing and scientific issues affecting the nucleic acid testing market. In this presentation, attendees learned what factors have an impact on the Dx / Rx market environment, including drug development approaches, diagnostic company opportunities, and payer reimbursement risk. Click here for more information.

SwedenBio’s Swedish - US Medtech Seminar/How to Enter and Succeed in the US Marketplace: Reimbursement Planning and Implementation in a Competitive Market
November 13th 2007, Stockholm, Sweden
Speaker: Rob Wenthold, Director – attendees learned how to successfully launch medical devices in the US market. Participants were given insight on the US regulatory and reimbursement system as well as learned overall market strategies. Click here for more information.

Q1 Productions Presents the Medical Device Coverage & Reimbursement Conference: Hard-Wiring Evidence-Based Medicine Principles into Reimbursement Planning for Medical Devices
October 30th 2007, Chicago, Illinois
Speaker: Erica Bisguier, Executive Director – As medical technologies become more complex and information technology systems more sophisticated, public and private payers are increasingly relying on comprehensive clinical and economic evidence to drive coverage and payment. Many payers have developed rigorous technology assessment processes that can either facilitate or impede clinician and market access. This session provided suggestions for the practical application of EBM in clinical development, commercialization activities, and timelines. Click here to learn more.

The Center for Business Intelligence’s 2nd Annual Forum on Effective Oncology Benefit Management: Best Practices and Strategies for Managing Oncology Therapeutic Classes – Results from a Survey of Planned Decision Makers
October 18th 2007, Chicago, Illinois
Speaker: Rob Wenthold, Director – It is a considerable challenge to design an oncology benefit program that encompasses the balances for promoting the most economical treatment options while ensuring decision making on a case by case basis. In this session, participants heared the results of a study of managed care decision makers who are wrestle with these issues every day. They learned a variety of perspectives and learned about the strategies and practices that other health plans are utilizing in the management of oncology benefits and providing access to quality care for all cancer patients. Click here for more information.

National Institutes of Health Commercialization Assistance Program (NIH-CAP) Commercialization Training Workshop: Breakout Session, Strategies for Fast Growing Companies
October 17th 2007, Marina del Rey, CA
Conference Panelist: Erica Bisguier, Executive Director – The NIH-CAP is a national program funded by NIH and managed by the Larta Institute to assist some of the most promising life sciences companies bring their technologies to market. This seminar helped broaden the strategic thinking of companies by addressing topics such as the FDA regulatory process and reimbursement issues for biotech/pharmaceutical, medical device, and diagnostic companies. Is your business on the right path and are you addressing the most critical issues for commercialization success? Click here for more information.

Facts About Medicare Conditional Coverage: The National Coverage Determination on Clinical Research & Medicare’s Policy on Coverage with Evidence Development
October 16th 2007
Webinar Speaker: Erica Bisguier, Executive Director – learn the history of Medicare’s stance on covering items and services that are either in clinical trials or have not yet gained widespread utilization because they are new to the market. Participants learned the importance of gaining Medicare coverage for an item or service, what it means to gain coverage under the Clinical Research Policy NCD, and the strategies that companies should initiate in order to engage with the Centers for Medicare and Medicaid Services (CMS) regarding coverage. The webinar gave an overview of Medicare coverage and definitions and the key activities for companies with new products to engage in with CMS. Click here for more information.